Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of HealthGlobeNewsWire • 05/01/25
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025GlobeNewsWire • 04/22/25
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mgGlobeNewsWire • 03/20/25
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalGlobeNewsWire • 03/19/25
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure ProductsGlobeNewsWire • 03/18/25
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness ProgramsGlobeNewsWire • 03/13/25
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product CandidatesGlobeNewsWire • 03/12/25
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalGlobeNewsWire • 03/10/25
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/03/25
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025GlobeNewsWire • 02/18/25
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New OrleansGlobeNewsWire • 02/07/25
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma PharmaceuticalsGlobeNewsWire • 01/14/25
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for EbolaGlobeNewsWire • 01/13/25
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025GlobeNewsWire • 01/08/25
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)GlobeNewsWire • 01/08/25